Analyst Price Target is $16.00
▲ +101.77% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Foghorn Therapeutics in the last 3 months. The average price target is $16.00, with a high forecast of $20.00 and a low forecast of $9.00. The average price target represents a 101.77% upside from the last price of $7.93.
Current Consensus is
Moderate Buy
The current consensus among 5 contributing investment analysts is to moderate buy stock in Foghorn Therapeutics. This Moderate Buy consensus rating has held steady for over two years.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
